Literature DB >> 2916444

Plasma cholecystokinin and pancreatic polypeptide responses after ingestion of a liquid test meal rich in medium-chain fatty acids in patients with chronic pancreatitis.

I Nakano1, A Funakoshi, H Shinozaki, K Sakai.   

Abstract

Plasma cholecystokinin (CCK) and human pancreatic polypeptide (hPP) responses after ingestion of a liquid test meal rich in medium-chain fatty acids (MCFA) were studied in patients with chronic pancreatitis with or without diabetes mellitus (DM). Integrated response of plasma CCK was significantly lower in patients with chronic pancreatitis and DM than in the two other groups. There was no statistically significant difference between the healthy control subjects and the patients with chronic pancreatitis without DM in the integrated responses of hPP and plasma CCK. These results indicate that diabetic patients with a greatly destroyed pancreas do not release as much CCK as do nondiabetic patients with a mildly impaired pancreas. An MCFA meal is therefore considered safe in patients with a mildly impaired pancreas. For diabetic patients, however, care should be taken not to exacerbate the DM.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916444     DOI: 10.1093/ajcn/49.2.247

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  3 in total

1.  Plasma cholecystokinin levels in Prader-Willi syndrome and obese subjects.

Authors:  M G Butler; M G Carlson; D E Schmidt; I D Feurer; T Thompson
Journal:  Am J Med Genet       Date:  2000-11-06

2.  Plasma pancreastatin responses after intrajejunal infusion of liquid meal in patients with chronic pancreatitis.

Authors:  A Funakoshi; K Tateishi; H Shinozaki; K Miyasaka; T Ito; H Wakasugi
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

3.  Acetylcholine regulates glucagon secretion from human glucagonoma cells.

Authors:  A Funakoshi; Y Yasunami; S Ryu; H Shinozaki; A Jimi; S Ikeda
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.